Drug treatment adherence is one of the biggest issues in tuberculosis (TB) treatment. Including DOTS (Directly Observed Treatment, Short-course) program, many programs for TB cases have yielded marginal success and the new drug resistance varieties of TB persist. During the 1960s, researchers have projected naphthoquinone–mercuric chloride (N-M) test as the single most way to objectively track the presence of isoniazid (INH) in urine and hence treatment adherence. INH is metabolised by cytochrome P450s and usually cleared from body within 8 h. Hence, the typical INH levels in biological fluids are within 1–5 μg/ml. The N-M test practically works at 10–50 μg/ml and the authors developed the sodium polyacrylate (SPA) as a solid surface to improve detection limit of INH by 6–10 fold. The modification involves absorbing the reagents of N-M test on the SPA surface and lyophilised material is directly used for diagnosis. The dry beads can detect 1–2 μg/ml of INH in saliva. The test performed with spiked as well as clinical samples and the results have good correlation. This new test has a realistic chance of tracking the TB treatment adherence remotely and in that direction a system was projected for implementation.

References

1. 1)
  - 36. Macfadyen, D.M., Heffernan, J.F.: ‘Urine testing for isoniazid in the supervision of out-patient oral chemotherapy for pulmonary tuberculosis. The failure of a routine service’, Bull. World Health Organ., 1967, 36, (5), pp. 847–852.
2. 2)
  - 17. OBrien, J.K., Doerfler, M.E., Harkin, T.J., et al: ‘Isoniazid levels in the bronchoalveolar lavage fluid of patients with pulmonary tuberculosis’, Lung, 1998, 176, (3), pp. 205–211.
3. 3)
  - 21. Prasad, S., Agarwal, R.K.: ‘Nickel(II) complexes of hydrazone of isoniazid and their magneto-spectral, electrochemical, thermal and antimicrobial investigations’, Res. Lett. Inorg. Chem., 2008, 2008, pp. 1–5.
4. 4)
  - 2. Espinal, M.A.: ‘The global situation of MDR-TB’, Tuberculosis, 2003, 83, (1-3), pp. 44–51.
5. 5)
  - 39. Khalafy, J., Bruce, J.M.: ‘Oxidative dehydrogenation of 1-tetralones: synthesis of juglone, naphthazarin, and Α-hydroxyanthraquinones’, J. Sci. Islam. Repub. Iran, 2002, 13, (2), pp. 131–139.
6. 6)
  - 40. Couladouros, E.A., Strongilos, A.T.: ‘Regioselective oxidation of 3-monosubstituted juglone derivatives’, Tetrahedron Lett., 2000, 41, (4), pp. 535–538.
7. 7)
  - 7. Mariam, S.H., Werngren, J., Aronsson, J., et al: ‘Dynamics of antibiotic resistant mycobacterium tuberculosis during long-term infection and antibiotic treatment’, PLoS One, 2011, 6, (6), p. e21147.
8. 8)
  - 30. Sadeg, N., Pertat, N., Dutertre, H., et al: ‘Rapid, specific and sensitive method for isoniazid determination in serum’, J. Chromatogr. B Biomed. Sci. Appl., 1996, 675, (1), pp. 113–117.
9. 9)
  - 9. Moonan, P.K., Quitugua, T.N., Pogoda, J.M., et al: ‘Does directly observed therapy (DOT) reduce drug resistant tuberculosis?’, BMC Public Health, 2011, 11, (1), p. 19.
10. 10)
  - 42. Evgen'Ev, M.I., Garmonov, S.Y., Evgen'Eva, I.I., et al: ‘Reversed-phase liquid chromatographic determination of isoniazide in human urine as a test of the genetically predetermined type of biotransformation by acetylation’, Talanta, 1998, 47, (4), pp. 891–898.
11. 11)
  - 3. Fauci, A.S.: ‘Multidrug-resistant and extensively drug-resistant tuberculosis: the national institute of allergy and infectious diseases research agenda and recommendations for priority research’, J. Infect. Dis., 2008, 197, (11), pp. 1493–1498.
12. 12)
  - 41. Khuhawar, M.Y., Rind, F.M.A.: ‘Liquid chromatographic determination of isoniazid, pyrazinamide and rifampicin from pharmaceutical preparations and blood’, J. Chromatogr. B Anal. Technol. Biomed. Life Sci., 2002, 766, (2), pp. 357–363.
13. 13)
  - 37. Hua, F., Qian, M.: ‘Synthesis of self-crosslinking sodium polyacrylate hydrogel and water-absorbing mechanism’, J. Mater. Sci., 2001, 36, (4), pp. 731–738.
14. 14)
  - 14. Shrivastava, S.R., Shrivastava, P.S., Ramasamy, J.: ‘Assessing the utility of contact tracing in reducing the magnitude of tuberculosis’, Infect. Ecol. Epidemiol., 2014, 4, pp. 3–4.
15. 15)
  - 28. Kulkarni, R.M., Bilehal, D.C., Nandibewoor, S.T.: ‘Oxidation of isoniazid by quinolinium dichromate in an aqueous acid medium and kinetic determination of isoniazid in pure and pharmaceutical formulations’, Anal. Sci., 2004, 20, (4), pp. 743–747.
16. 16)
  - 27. Naik, R.M., Prasad, S., Kumar, B., et al: ‘Ligand substitution kinetic assay of antitubercular drug isoniazid in pure and pharmaceutical formulations’, Microchem. J., 2013, 111, pp. 108–115.
17. 17)
  - 38. Zhuang, W., Li, L., Liu, C.: ‘Effects of sodium polyacrylate on water retention and infiltration capacity of a sandy soil’, Springerplus, 2013, 2, (Suppl 1), pp. S11–S10.
18. 18)
  - 11. Brewer, T.F., Heymann, S.J.: ‘To control and beyond: moving towards eliminating the global tuberculosis threat’, J. Epidemiol. Community Health, 2004, 58, (10), pp. 822–825.
19. 19)
  - 19. Gangadharam, P.R.J., Narayanan Nair, C., Subbaiah, T.V: ‘A simple paper test for isoniazid in urine’, Indian J. Tuberc., 1962, 9, (4), pp. 219–223.
20. 20)
  - 16. Barclay, E.: ‘Text messages could hasten tuberculosis drug compliance’, Lancet, 2009, 373, (9657), pp. 15–16.
21. 21)
  - 15. Hoffman, J.A., Cunningham, J.R., Suleh, A.J., et al: ‘Mobile direct observation treatment for tuberculosis patients. A technical feasibility pilot using mobile phones in Nairobi, Kenya’, Am. J. Prev. Med., 2010, 39, (1), pp. 78–80.
22. 22)
  - 6. Lillebaek, T., Andersen, A.B., Bauer, J., et al: ‘Risk of mycobacterium tuberculosis transmission in a low-incidence country due to immigration from high-incidence areas’, J. Clin. Microbiol., 2001, 39, (3), pp. 855–861.
23. 23)
  - 25. Gangadharam, J.R.P., Mitchison, A.D., Subbaiah, V.: ‘The detection of isoniazid in urine’, Tubercle, 1957, 39, pp. 191–200.
24. 24)
  - 18. van den Boogaard, J., Lyimo, R.A., Boeree, M.J., et al: ‘Electronic monitoring of treatment adherence and validation of alternative adherence measures in tuberculosis patients: a pilot study’, Bull. World Health Organ., 2011, 89, (9), pp. 632–639.
25. 25)
  - 5. Thomas, A., Ramachandran, R., Rehaman, F., et al: ‘Management of multi drug resistance tuberculosis in the field: tuberculosis research centre experience’, Indian J. Tuberc., 2007, 54, pp. 117–124.
26. 26)
  - 12. Tang, S., Tan, S., Yao, L., et al: ‘Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: retrospective multi-center investigation’, PLoS One, 2013, 8, (12), pp. 1–8.
27. 27)
  - 32. Boxenbaum, H.G., Bekersky, I., Mattaliano, V., et al: ‘Plasma and salivary concentrations of isoniazid in man: preliminary findings in two slow acetylator subjects’, J. Pharmacokinet. Biopharm., 1975, 3, (6), pp. 443–456.
28. 28)
  - 23. Kriza, A., Ababei, L.V., Cioatera, N., et al: ‘Synthesis and structural studies of complexes of Cu, Co, Ni and Zn with isonicotinic acid hydrazide and isonicotinic acid (1-naphthylmethylene)hydrazide’, J. Serbian Chem. Soc., 2010, 75, (2), pp. 229–242.
29. 29)
  - 8. Anuwatnonthakate, A., Limsomboon, P., Nateniyom, S., et al: ‘Directly observed therapy and improved tuberculosis treatment outcomes in Thailand’, PLoS One, 2008, 3, (8), p. e3089.
30. 30)
  - 10. Kironde, S., Bajunirwe, F.: ‘Lay workers in directly observed treatment (DOT) programmes for tuberculosis in high burden settings: should they be paid? A review of behavioural perspectives’, Afr Health Sci., 2002, 2, (2), pp. 73–78.
31. 31)
  - 26. Gurumurthy, P., Rahman, F.: ‘Salivary levels in tuberculous of isoniazid patients and rifampicin’, Tubercle, 1990, 71, pp. 29–33.
32. 32)
  - 33. Kraus, P., Krausová, E., Šimáně, Z.: ‘A new urine test for the control of isoniazid therapy’, Tubercle, 1961, 42, (4), pp. 516–520.
33. 33)
  - 20. Kraus, B.P., Krausov, E.V.A.: ‘The duration of positive UrhTary reaction after a ShTgle oral dose’, Tubercle, 1965, 46, pp. 206–208.
34. 34)
  - 1. Sharma, S.K., Mohan, A: ‘Multidrug-resistant tuberculosis’, Indian J. Med. Res., 2004, 120, (4), pp. 354–376.
35. 35)
  - 29. Yao, S., Li, W., Su, X., et al: ‘A sensitive and specific method for isoniazid determination based on selective adsorption using an isoniazid ion-selective piezoelectric sensor’, Talanta, 1999, 50, (3), pp. 469–480.
36. 36)
  - 31. Korath, M.P., Jagadeesan, K.: ‘Determination of isoniazid concentration in saliva by a simple spectrofluorimetric method’, Bombay Hosp. J., 2011, 53, (Special Issue), pp. 321–325.
37. 37)
  - 34. Ellard, G.A., Gammon, P.T., Wallace, S.M.: ‘The determination of isoniazid and its metabolites acetylisoniazid, monoacetylhydrazine, diacetylhydrazine, isonicotinic acid and isonicotinylglycine in serum and urine’, Biochem. J., 1972, 126, (3), pp. 449–458.
38. 38)
  - 13. Grindrod, K.A., Li, M., Gates, A.: ‘Evaluating user perceptions of mobile medication management applications with older adults: A usability study’, J. Med. Internet Res., 2014, 16, (3), pp. 1–26.
39. 39)
  - 35. Venkataraman, P., Eidus, L.: ‘A comparison of various methods for the detection of isoniazid and its metabolites in urine’, Tubercle, 1965, 46, pp. 262–269.
40. 40)
  - 22. Cozzi, P.G.: ‘Metal-salen schiff base complexes in catalysis: practical aspects’, Chem. Soc. Rev., 2004, 33, (7), pp. 410–421.
41. 41)
  - 24. Shetty, D.N., Narayana, B., Samshuddin, S.: ‘Novel reagents for the spectrophotometric determination of Isoniazid’, ISRN Spectrosc., 2012, 2012, pp. 1–5.
42. 42)
  - 4. Michael, J.S., John, T.J.: ‘Extensively drug-resistant tuberculosis in India: a review’, Indian J. Med. Res., 2012, 136, (4), pp. 599–604.

Objective measurement of isoniazid levels: practical approach for monitoring tuberculosis drug treatment adherence

References

Related content